Making Do With What We Have

Authors from the FDA described data submitted to the FDA Adverse Event Reporting System on 29 patients receiving HCV treatment with DAA–based regimens who had reactivation of hepatitis B virus. The editorialist discusses the clinical implications of the findings regarding safety reporting after a drug's approval.

http://ift.tt/2oZ0nyu